Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
ANRO Stock Chart & Stats
$15.22
-$0.09(-1.99%)
At close: 4:00 PM EST
$15.22
-$0.09(-1.99%)
Day’s Range― - ―
52-Week Range$1.60 - $20.91
Previous CloseN/A
Volume104.17K
Average Volume (3M)2.30M
Market Cap
$472.83M
Enterprise Value$362.54M
Total Cash (Recent Filing)$137.82M
Total Debt (Recent Filing)$27.52M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding31,066,336
10 Day Avg. Volume557,199
30 Day Avg. Volume2,303,174
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.69
Price to Sales (P/S)0.00
P/FCF Ratio-2.10
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-599.23
Enterprise Value/Ebitda-6.10
Forecast
1Y Price Target
$35.67Price Target Upside134.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ALTO-207 Acquisition And DosingAnalyst notes that ALTO-207's combination of pramipexole with ondansetron permits faster titration to effective doses while reducing dose-limiting side effects, which could improve tolerability and commercial differentiation in treatment-resistant depression.
Clinical Readouts And ALTO-300Analyst points to program readouts, including the Phase IIb ALTO-300 adjunctive study, as key catalysts because positive results showing enhanced dopamine activity and circadian resynchronization with a benign safety profile could materially boost investor sentiment.
Precision BiomarkersAnalyst highlights that Alto's biomarker-driven precision psychiatry platform can identify patient subgroups more likely to respond to specific drug mechanisms, improving clinical trial success odds and enabling a stronger label if approvals are achieved.
Bears Say
Alto Neuroscience, Inc. News
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $1.60 and its highest was $20.91 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $472.83M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is May 20, 2026 which is in 99 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Oct 31, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.668 by $0.148.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 31,066,336 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.668. Following the earnings report the stock price went down -0.908%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alto Neuroscience, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.67 (134.36% Upside)
$35.67 (134.36% Upside)
Hedge Fund Trend
Increased
By 155.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.39%
12-Months-Change
Fundamentals
Return on Equity
-45.01%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
ANRO Stock 12 Month Forecast
Average Price Target
$35.67
▲(134.36% Upside)
Technical Analysis
Cassava Sciences
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Ownership Overview
8.00%
Insiders
5.38% Mutual Funds
27.34% Other Institutional Investors
54.87% Public Companies and
Individual Investors